FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Justus Duyster

Research Profile

Living Beings

Mouse

Chemicals & Drugs

Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Anatomy

Physiology

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Jan van Noesel; Theo A M van Os; Jitske Weegenaar; Justus Duyster; Rama K Kancha; Peter W A Kunst; Roy J A Reinten; Ward H van der Ven; Carel J M van Noesel
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Anna Lena Illert; Stefanie Kreutmair; Cathrin Moll; Christian Peschel; Michael Zech; Corinna Albers; Florian Bassermann; Justus Duyster
Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M.
Anna Lena Illert; Hiroyuki Kawaguchi; Stephan W Morris; Christian Peschel; Letitia Quintanilla-Martinez; Christine von Klitzing; Cristina Antinozzi; Marco Barchi; Florian Bassermann; Dirk G de Rooij; Mitsuteru Hiwatari; Justus Duyster
Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Justus Duyster (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jan van Noesel; Theo A M van Os; Jitske Weegenaar; Justus Duyster; Rama K Kancha; Peter W A Kunst; Roy J A Reinten; Ward H van der Ven; Carel J M van Noesel
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(10):e161-4.
2012: Anna Lena Illert; Stefanie Kreutmair; Cathrin Moll; Christian Peschel; Michael Zech; Corinna Albers; Florian Bassermann; Justus Duyster
Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M.
The Journal of biological chemistry 2012;287(45):37997-8005.
2012: Anna Lena Illert; Hiroyuki Kawaguchi; Stephan W Morris; Christian Peschel; Letitia Quintanilla-Martinez; Christine von Klitzing; Cristina Antinozzi; Marco Barchi; Florian Bassermann; Dirk G de Rooij; Mitsuteru Hiwatari; Justus Duyster
Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase.
Development (Cambridge, England) 2012;139(14):2523-34.
2012: Hannes Leischner; Christian Peschel; Elena Razumovskaya; Lars Rönnstrand; Karsten Spiekermann; Corinna Albers; Stefan Bohlander; K Götze; Rebekka Grundler; Justus Duyster
SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Blood 2012;119(17):4026-33.
2012: Heikki Joensuu; Raija Kallio; Mika Leinonen; OR Monge; Bengt Nilsson; Daniel Pink; Giuliano Ramadori; Salah-Eddin Al-Batran; Thor A Alvegård; Sebastian Bauer; Petri Bono; Justus Duyster; Mikael Eriksson; Jörg T Hartmann; Peter Hohenberger; Maarit Sarlomo-Rikala; Marcus Schlemmer; Jochen Schütte; Harri Sihto; Kirsten Sundby Hall; Aki Vehtari; Eva Wardelmann; Peter Reichardt
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
JAMA : the journal of the American Medical Association 2012;307(12):1265-72.
2012: Susanne Kratzat; Cornelius Miething; Viktoriya Nikolova; Jonas Nilsson; Christian Peschel; Elke Pietschmann; Jürgen Ruland; Stephanie Schoeffmann; Justus Duyster; Oliver Gorka; Alexander Hoellein; Anna-Lena Illert; Ulrich Keller
Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies.
PloS one 2012;7(5):e37433.
2011: Corinna Albers; Anna L Illert; Hannes Leischner; Cornelius Miething; Christian Peschel; Melanie Thiede; Justus Duyster
An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis.
Blood 2011;118(8):2200-10.
2011: Robert S Benjamin; Jean-Yves Blay; Binh Nguyen Bui; Justus Duyster; Jörg Thomas Hartmann; Sheryl McCoy; Peter Reichardt; Lee S Rosen; Patrick Schöffski; Scott M Schuetze; Keith Skubitz; Daniel E Stepan; Yu-Nien Sun; Allan Van Oosterom; Laurence H Baker
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Cancer chemotherapy and pharmacology 2011;68(1):69-77.
2011: Nikolas von Bubnoff; S P Gorantla; R A Engh; T M Oliveira; S Thöne; E Aberg; Christian Peschel; Justus Duyster
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Oncogene 2011;30(8):933-43.
2011: Rama Krishna Kancha; Christian Peschel; Justus Duyster
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(2):387-92.
2011: Rama Krishna Kancha; Christian Peschel; Nikolas von Bubnoff; Natalie Bartosch; Richard A Engh; Justus Duyster
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
PloS one 2011;6(10):e26760.
2010: Sivahari P Gorantla; Tobias N Dechow; Rebekka Grundler; Anna Lena Illert; Christian Meyer zum Büschenfelde; Marcus Kremer; Christian Peschel; Justus Duyster
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
Blood 2010;116(22):4600-11.
2010: Sabina Berezowska; Simone Diermeier-Daucher; Gero Brockhoff; Raymonde Busch; Justus Duyster; Anca-Ligia Grosu; Jürgen Schlegel
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
International journal of molecular medicine 2010;26(5):713-21.
2010: Maya Koren-Michowitz; Philipp le Coutre; Justus Duyster; Christof Scheid; Panayiotis Panayiotidis; Witold Prejzner; Jacob M Rowe; Michaela Schwarz; Neta Goldschmidt; Arnon Nagler
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Cancer 2010;116(19):4564-72.
2010: Jürgen den Hollander; Sara Rimpi; Joanne R Doherty; Martina Rudelius; Andreas Buck; Alexander Hoellein; Marcus Kremer; Nikolas Graf; Markus Scheerer; Mark A Hall; Andrei Goga; Nikolas von Bubnoff; Justus Duyster; Christian Peschel; John L Cleveland; Jonas A Nilsson; Ulrich Keller
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.
Blood 2010;116(9):1498-505.
2010: Nikolas von Bubnoff; C Rummelt; H Menzel; M Sigl; Christian Peschel; Justus Duyster
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
Leukemia 2010;24(8):1523-5.
2010: Anja Baumgart; Stefan Seidl; Petros Vlachou; Lars Michel; Nadya Mitova; Nicole Schatz; Katja Specht; Ina Koch; Tibor Schuster; Rebekka Grundler; Marcus Kremer; Falko Fend; Jens T Siveke; Christian Peschel; Justus Duyster; Tobias Dechow
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
Cancer research 2010;70(13):5368-78.
2010: Natasa Anastasov; Irina Bonzheim; Martina Rudelius; Margit Klier; Therese Dau; Daniela Angermeier; Justus Duyster; Stefania Pittaluga; Falko Fend; Mark Raffeld; Leticia Quintanilla-Martinez
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
Haematologica 2010;95(5):760-7.
2010: Ulrich Keller; Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy.
Journal of cellular and molecular medicine 2010;14(4):805-17.
2010: Sandra C Haas; René Huber; Romina Gutsch; Judith D Kandemir; Christian Cappello; Jürgen Krauter; Justus Duyster; Arnold Ganser; Korbinian Brand
ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling modules.
British journal of haematology 2010;148(5):777-90.
2010: Nikolas von Bubnoff; Justus Duyster
Chronic myelogenous leukemia: treatment and monitoring.
Deutsches Ärzteblatt international 2010;107(7):114-21.
2010: Mareike Verbeek; Falko Fend; Thomas Licht; Christian Meyer zum Büschenfelde; Jens Stollfuss; Christian Peschel; Justus Duyster
T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST.
Nature reviews. Clinical oncology 2010;7(2):116-9.
2009: Srinivasa Rao Bandi; Christian Brandts; Marion Rensinghoff; Rebekka Grundler; Lara Tickenbrock; Gabriele Köhler; Justus Duyster; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve; Bülent Sargin
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Blood 2009;114(19):4197-208.
2009: Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster; Olaf Stüve; Bernhard Hemmer; Achim Berthele
Primary central nervous system lymphoma in a patient treated with natalizumab.
Annals of neurology 2009;66(3):403-6.
2009: Rebekka Grundler; Laurent Brault; Christelle Gasser; Alex N Bullock; Tobias Dechow; Sabine Woetzel; Vanda Pogacic; Antonello Villa; Sabine Ehret; Georgina Berridge; Anke Spoo; Christine Dierks; Andrea Biondi; Stefan Knapp; Justus Duyster; Juerg Schwaller
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
The Journal of experimental medicine 2009;206(9):1957-70.
2009: Frank Breitenbuecher; Susanne Schnittger; Rebekka Grundler; Boyka Markova; Birgit Carius; Alexandra Brecht; Justus Duyster; Torsten Haferlach; Christoph Huber; Thomas Fischer
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood 2009;113(17):4074-7.
2009: Nikolas von Bubnoff; Richard A Engh; Espen Aberg; Jana Sänger; Christian Peschel; Justus Duyster
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Cancer research 2009;69(7):3032-41.
2009: Carola Reindl; Hilmar Quentmeier; Konstantin Petropoulos; Philipp A Greif; Tobias Benthaus; Bob Argiropoulos; Gudrun Mellert; Sridhar Vempati; Justus Duyster; Christian Buske; Stefan K Bohlander; Keith R Humphries; Wolfgang Hiddemann; Karsten Spiekermann
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2238-47.
2009: Florian Heidel; Daniel B Lipka; Fian K Mirea; Siavosh Mahboobi; Rebekka Grundler; Rama Krishna Kancha; Justus Duyster; Michael Naumann; Christoph Huber; Frank D Böhmer; Thomas Fischer
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
British journal of haematology 2009;144(6):865-74.
2009: Rama Krishna Kancha; Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):460-7.
2008: Rama Krishna Kancha; Nikolas von Bubnoff; Cornelius Miething; Christian Peschel; Katharina S Götze; Justus Duyster
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Haematologica 2008;93(11):1718-22.
2008: S Fanta; M Sonnenberg; I Skorta; Justus Duyster; C Miething; Walter Aulitzky; Heiko van der Kuip
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Oncogene 2008;27(31):4380-4.
2008: Anja Bremm; Axel Walch; Margit Fuchs; Jörg Mages; Justus Duyster; Gisela Keller; Christine Hermannstädter; Karl-Friedrich Becker; Sandra Rauser; Rupert Langer; Claus Hann von Weyhern; Heinz Höfler; Birgit Luber
Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
Cancer research 2008;68(3):707-14.
2007: Rama Krishna Kancha; Rebekka Grundler; Christian Peschel; Justus Duyster
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Experimental hematology 2007;35(10):1522-6.
2007: Florian Scheich; Justus Duyster; Christian Peschel; Helga Bernhard
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
Blood 2007;110(7):2556-60.
2007: Florian R Greten; Melek C Arkan; Julia Bollrath; Li-Chung Hsu; Jason Goode; Cornelius Miething; Serkan I Göktuna; Michael Neuenhahn; Joshua Fierer; Stephan Paxian; Nico van Rooijen; Yajun Xu; Timothy O'Cain; Bruce B Jaffee; Dirk H Busch; Justus Duyster; Roland M Schmid; Lars Eckmann; Michael Karin
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta.
Cell 2007;130(5):918-31.
2007: Bülent Sargin; Chunaram Choudhary; Nicola Crosetto; Mirko H H Schmidt; Rebekka Grundler; Marion Rensinghoff; Christine Thiessen; Lara Tickenbrock; Joachim Schwäble; Christian Brandts; Benjamin August; Steffen Koschmieder; Srinivasa Rao Bandi; Justus Duyster; Wolfgang E Berdel; Carsten Müller-Tidow; Ivan Dikic; Hubert Serve
Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Blood 2007;110(3):1004-12.
2007: H Menzel; Nikolas von Bubnoff; Andreas Hochhaus; C Haferlach; Christian Peschel; Justus Duyster
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
Bone marrow transplantation 2007;40(1):83-4.
2007: Ken Herrmann; Hinrich A Wieder; Andreas K Buck; Marion Schöffel; Bernd J Krause; Falko Fend; Tibor Schuster; Christian Meyer zum Büschenfelde; Hans-Jürgen Wester; Justus Duyster; Christian Peschel; Markus Schwaiger; Tobias Dechow
Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3552-8.
2007: Florian Bassermann; Christine von Klitzing; Anna Lena Illert; Silvia Münch; Stephan W Morris; Michele Pagano; Christian Peschel; Justus Duyster
Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1.
The Journal of biological chemistry 2007;282(22):15965-72.
2007: Cornelius Miething; Rebekka Grundler; Claudia Mugler; Simone Brero; Josef Hoepfl; Jochen Geigl; Michael R Speicher; Oliver G Ottmann; Christian Peschel; Justus Duyster
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(11):4594-9.
2007: Florian Krötz; Matthias Keller; Sabine Derflinger; Holger Schmid; Torsten Gloe; Florian Bassermann; Justus Duyster; Clemens D Cohen; Christoph Schuhmann; Volker Klauss; Ulrich Pohl; Hans-Ulrich Kreider-Stempfle; Hae-Young Sohn
Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism.
Hypertension 2007;49(1):201-8.
2006: Cornelius Miething; Christian Peschel; Justus Duyster
Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options.
Current drug targets 2006;7(10):1329-34.
2006: Leticia Quintanilla-Martinez; Stefania Pittaluga; Cornelius Miething; Margit Klier; Martina Rudelius; Theresa Davies-Hill; Natasa Anastasov; Antonio Martinez; Angelica Vivero; Justus Duyster; Elaine S Jaffe; Falko Fend; Mark Raffeld
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
Blood 2006;108(6):2029-36.
2006: Gerhard H Simon; Heike E Daldrup-Link; Juli Kau; Stephan Metz; Jürgen Schlegel; Guido Piontek; Olaf Saborowski; Stavros Demos; Justus Duyster; Bernd J Pichler
Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe.
European journal of nuclear medicine and molecular imaging 2006;33(9):998-1006.
2006: Nikolas von Bubnoff; Paul W Manley; Jürgen Mestan; Jana Sanger; Christian Peschel; Justus Duyster
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Blood 2006;108(4):1328-33.
2006: Thomas Horn; Marcus Kremer; Tobias Dechow; Walther M Pfeifer; Birgit Geist; Michael Perker; Justus Duyster; Leticia Quintanilla-Martinez; Falko Fend
Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
The Journal of molecular diagnostics : JMD 2006;8(3):299-304.
2006: Nikolas von Bubnoff; Sivahari Prasad Gorantla; Silvia Thöne; Christian Peschel; Justus Duyster
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
Blood 2006;107(12):4970-1; author reply 4972.
2006: Myriam Adam; Vanda Pogacic; Marina Bendit; Richard Chappuis; Martijn C Nawijn; Justus Duyster; Casey J Fox; Craig Thompson; Jan Cools; Juerg Schwaller
Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Cancer research 2006;66(7):3828-35.
2006: Cornelius Miething; S Feihl; Claudia Mugler; Rebekka Grundler; Nikolas von Bubnoff; F Lordick; Christian Peschel; Justus Duyster
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.
Leukemia 2006;20(4):650-7.
2005: Philipp J Jost; Svenja M Stengel; Wolfgang Huber; Mario Sarbia; Christian Peschel; Justus Duyster
Very severe iron-deficiency anemia in a patient with celiac disease and bulimia nervosa: a case report.
International journal of hematology 2005;82(4):310-1.
2005: Florian Bassermann; Christian Peschel; Justus Duyster
Mitotic entry: a matter of oscillating destruction.
Cell cycle (Georgetown, Tex.) 2005;4(11):1515-7.
2005: Andreas Burchert; Ying Wang; Dali Cai; Nikolas von Bubnoff; P Paschka; Sabine Müller-Brüsselbach; O G Ottmann; Justus Duyster; Andreas Hochhaus; Andreas Neubauer
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Leukemia 2005;19(10):1774-82.
2005: J Dengler; Nikolas von Bubnoff; T Decker; Christian Peschel; Justus Duyster
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib.
Leukemia 2005;19(10):1835-8.
2005: Nikolas von Bubnoff; S H P Gorantla; Rama Krishna Kancha; F Lordick; Christian Peschel; Justus Duyster
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.
Leukemia 2005;19(9):1670-1.
2005: Florian Bassermann; Christine von Klitzing; Silvia Münch; RENYUAN BAI; Hiroyuki Kawaguchi; Stephan W Morris; Christian Peschel; Justus Duyster
NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry.
Cell 2005;122(1):45-57.
2005: Rebekka Grundler; Cornelius Miething; Christian Thiede; Christian Peschel; Justus Duyster
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Blood 2005;105(12):4792-9.
2005: Florian Krötz; Barbara Engelbrecht; Martin A Buerkle; Florian Bassermann; Hanna Bridell; Torsten Gloe; Justus Duyster; Ulrich Pohl; Hae-Young Sohn
The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation.
Journal of the American College of Cardiology 2005;45(10):1700-6.
2005: Ulrike Hartmann; Stefan Balabanov; Patrick Ziegler; Jörg Fellenberg; Heiko van der Kuip; Justus Duyster; Hans-Peter Lipp; Carsten Bokemeyer; Lothar Kanz; Tim H Brümmendorf
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
Experimental hematology 2005;33(5):542-9.
2005: Susanne Urschel; Florian Bassermann; RENYUAN BAI; Silvia Münch; Christian Peschel; Justus Duyster
Phosphorylation of grb10 regulates its interaction with 14-3-3.
The Journal of biological chemistry 2005;280(17):16987-93.
2005: Nikolas von Bubnoff; Simone Barwisch; Michael R Speicher; Christian Peschel; Justus Duyster
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.
Cell cycle (Georgetown, Tex.) 2005;4(3):400-6.
2005: Nikolas von Bubnoff; Darren R Veach; Heiko van der Kuip; Walter Aulitzky; Jana Sänger; Petra Seipel; William G Bornmann; Christian Peschel; Bayard Clarkson; Justus Duyster
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Blood 2005;105(4):1652-9.
2005: Nikolas von Bubnoff; Michael Sandherr; Günter Schlimok; R Andreesen; Christian Peschel; Justus Duyster
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.
Leukemia 2005;19(2):286-7.
2004: Nikolas von Bubnoff; Christian Peschel; Justus Duyster
[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].
Deutsche medizinische Wochenschrift (1946) 2004;129(40):2100-3.
2004: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Joachim Beck; Georg Hess; Birgit Weinkauf; Justus Duyster; Christian Peschel; Charles James Kirkpatrick; Matthias Theobald; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Blood 2004;103(10):3644-54.
2004: Andreas Burchert; Dali Cai; Lorenz C Hofbauer; Magnus K R Samuelsson; Emily P Slater; Justus Duyster; Markus Ritter; Andreas Hochhaus; Rolf Mueller; Martin Eilers; Manuel Schmidt; Andreas Neubauer
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Blood 2004;103(9):3480-9.
2004: Heiko van der Kuip; Alexandra Moehring; Lara Wohlbold; Cornelius Miething; Justus Duyster; Walter Aulitzky
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
Leukemia research 2004;28(4):405-8.
2004: Daniel Cussac; Catherine Greenland; Serge Roche; RENYUAN BAI; Justus Duyster; Stephan W Morris; Georges Delsol; Michèle Allouche; Bernard Payrastre
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
Blood 2004;103(4):1464-71.
2003: Nikolas von Bubnoff; Darren R Veach; W Todd Miller; Wanqing Li; Jana Sänger; Christian Peschel; William G Bornmann; Bayard Clarkson; Justus Duyster
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Cancer research 2003;63(19):6395-404.
2003: Lara Wohlbold; Heiko van der Kuip; Cornelius Miething; Hans-Peter Vornlocher; Cornelius Knabbe; Justus Duyster; Walter Aulitzky
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Blood 2003;102(6):2236-9.
2003: Cornelius Miething; Claudia Mugler; Rebekka Grundler; Josef Hoepfl; RENYUAN BAI; Christian Peschel; Justus Duyster
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Leukemia 2003;17(9):1695-9.
2003: Tao Ouyang; RENYUAN BAI; Florian Bassermann; Christine von Klitzing; Silvia Klumpen; Cornelius Miething; Stephan W Morris; Christian Peschel; Justus Duyster
Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
The Journal of biological chemistry 2003;278(32):30028-36.
2003: Cornelius Miething; Rebekka Grundler; Falco Fend; Josef Hoepfl; Claudia Mugler; Christoph von Schilling; Stephan W Morris; Christian Peschel; Justus Duyster
The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
Oncogene 2003;22(30):4642-7.
2003: Rebekka Grundler; Christian Thiede; Cornelius Miething; Christine Steudel; Christian Peschel; Justus Duyster
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Blood 2003;102(2):646-51.
2003: Dieter Kirchner; Justus Duyster; Oliver G Ottmann; Roland M Schmid; Lothar Bergmann; Gerd Munzert
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Experimental hematology 2003;31(6):504-11.
2003: Nikolas von Bubnoff; Christian Peschel; Justus Duyster
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Leukemia 2003;17(5):829-38.
2002: Ingo Ringshausen; Folker Schneller; Christian Bogner; Susanne Hipp; Justus Duyster; Christian Peschel; Thomas Decker
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.
Blood 2002;100(10):3741-8.
2002: U Keller; K S Götze; Justus Duyster; B Schmidt; S Rose-John; C Peschel
Murine stromal cells producing hyper-interleukin-6 and Flt3 ligand support expansion of early human hematopoietic progenitor cells without need of exogenous growth factors.
Leukemia 2002;16(10):2122-8.
2002: Josef Hoepfl; Cornelius Miething; Rebekka Grundler; K S Götze; Christian Peschel; Justus Duyster
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Leukemia 2002;16(9):1584-8.
2002: Thomas Jahn; Petra Seipel; Sunita Coutinho; Susanne Urschel; Kathleen Schwarz; Cornelius Miething; Hubert Serve; Christian Peschel; Justus Duyster
Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.
Oncogene 2002;21(29):4508-20.
2002: Margit Fuchs; Peter Hutzler; Ingrid Brunner; Jürgen Schlegel; Jörg Mages; Ute Reuning; Sandra Hapke; Justus Duyster; Setsuo Hirohashi; Takuya Genda; Michiie Sakamoto; Florian Uberall; Heinz Höfler; Karl-Friedrich Becker; Birgit Luber
Motility enhancement by tumor-derived mutant E-cadherin is sensitive to treatment with epidermal growth factor receptor and phosphatidylinositol 3-kinase inhibitors.
Experimental cell research 2002;276(2):129-41.
2002: Florian Bassermann; Thomas Jahn; Cornelius Miething; Petra Seipel; RENYUAN BAI; Sunita Coutinho; Victor L J Tybulewicz; Christian Peschel; Justus Duyster
Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
The Journal of biological chemistry 2002;277(14):12437-45.
2002: Thomas Decker; Folker Schneller; Susanne Hipp; Cornelius Miething; Thomas Jahn; Justus Duyster; Christian Peschel
Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
Leukemia 2002;16(3):327-34.
2002: RENYUAN BAI; Christina Koester; Tao Ouyang; Stephan Hahn; Matthias Hammerschmidt; Christian Peschel; Justus Duyster
SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling.
Nature cell biology 2002;4(3):181-90.
2002: Nikolas von Bubnoff; Folker Schneller; Christian Peschel; Justus Duyster
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
Lancet 2002;359(9305):487-91.
2002: Thomas Jahn; Petra Seipel; Susanne Urschel; Christian Peschel; Justus Duyster
Role for the adaptor protein Grb10 in the activation of Akt.
Molecular and cellular biology 2002;22(4):979-91.
2001: Thomas Jahn; Petra Seipel; Sunita Coutinho; Cornelius Miething; Christian Peschel; Justus Duyster
Grb4/Nckbeta acts as a nuclear repressor of v-Abl-induced transcription from c-jun/c-fos promoter elements.
The Journal of biological chemistry 2001;276(46):43419-27.
2001: Catherine Greenland; Christian Touriol; Grégory Chevillard; Stephan W Morris; RENYUAN BAI; Justus Duyster; Georges Delsol; Michèle Allouche
Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
Oncogene 2001;20(50):7386-97.
2001: Justus Duyster; RENYUAN BAI; Stephan W Morris
Translocations involving anaplastic lymphoma kinase (ALK).
Oncogene 2001;20(40):5623-37.
2001: Heiko van der Kuip; A W Goetz; Cornelius Miething; Justus Duyster; Walter Aulitzky
Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.
Blood 2001;98(5):1532-41.
2000: RENYUAN BAI; Tao Ouyang; Cornelius Miething; Stephan W Morris; Christian Peschel; Justus Duyster
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
Blood 2000;96(13):4319-27.
2000: T Jonuleit; Heiko van der Kuip; Cornelius Miething; H Michels; M Hallek; Justus Duyster; Walter Aulitzky
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Blood 2000;96(5):1933-9.
2000: Sunita Coutinho; Thomas Jahn; Marc Lewitzky; Stephan M Feller; P Hutzler; Christian Peschel; Justus Duyster
Characterization of Ggrb4, an adapter protein interacting with Bcr-Abl.
Blood 2000;96(2):618-24.
2000: C Duncker; Dagmar Dohr; Stephanie von Harsdorf; Justus Duyster; Martin Stefanic; C Martini; M Treiber; Bernd Hertenstein; J Novotny; R Arnold; Hermann Heimpel; Lothar Bergmann; Donald Bunjes
Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome.
Bone marrow transplantation 2000;25(12):1263-8.
2000: Carsten Oetzel; T Jonuleit; A Götz; Heiko van der Kuip; H Michels; Justus Duyster; M Hallek; Walter Aulitzky
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1958-68.
1999: Gabriele Hübinger; Inka Scheffrahn; Elke Müller; RENYUAN BAI; Justus Duyster; S W Morris; Hubert Schrezenmeier; Lothar Bergmann
The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Experimental hematology 1999;27(12):1796-805.
1998: RENYUAN BAI; P Dieter; Christian Peschel; Stephan W Morris; Justus Duyster
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
Molecular and cellular biology 1998;18(12):6951-61.
1998: RENYUAN BAI; Thomas Jahn; S Schrem; Gerd Munzert; K M Weidner; J Y Wang; Justus Duyster
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Oncogene 1998;17(8):941-8.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; T Westermeier; Thomas Flohr; D Desprès; Heinold Gamm; J Decker; G Derigs; Walter Aulitzky; Christoph Huber
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied.
Annals of hematology 1998;77(1-2):21-6.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; Sebastian Kreiter; Walter Aulitzky; Rüdiger Hehlmann; Christoph Huber
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
Bone marrow transplantation 1998;21(10):1029-36.
1997: HJ Gruss; Antonio Pinto; Justus Duyster; S Poppema; F Herrmann
Hodgkin's disease: a tumor with disturbed immunological pathways.
Immunology today 1997;18(4):156-63.
1996: Stéphane Ansieau; I Scheffrahn; G Mosialos; H Brand; Justus Duyster; K Kaye; J Harada; B Dougall; G Hübinger; E Kieff; F Herrmann; Achim Leutz; HJ Gruss
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(24):14053-8.
1996: C von Schilling; Justus Duyster; F Herrmann
[Progress in understanding the development of leukemia. Consequences for the clinic].
Der Internist 1996;37(10):971-81.
1996: HJ Gruss; I Scheffrahn; G Hubinger; Justus Duyster; F Hermann
The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.
Leukemia 1996;10(5):829-35.
1996: HJ Gruss; Justus Duyster; F Herrmann
Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():19-26.
1993: Justus Duyster; H Schwende; E Fitzke; H Hidaka; Peter Dieter
Different roles of protein kinase C-beta and -delta in arachidonic acid cascade, superoxide formation and phosphoinositide hydrolysis.
The Biochemical journal 1993;292 ( Pt 1)():203-7.
1993: Peter Dieter; E Fitzke; Justus Duyster
BAPTA induces a decrease of intracellular free calcium and a translocation and inactivation of protein kinase C in macrophages.
Biological chemistry Hoppe-Seyler 1993;374(3):171-4.
1992: Markus Grewe; Justus Duyster; Peter Dieter; H Henninger; Agnes Schulze-Specking; K Decker
Prostaglandin D2 and E2 syntheses in rat Kupffer cells are antagonistically regulated by lipopolysaccharide and phorbol ester.
Biological chemistry Hoppe-Seyler 1992;373(8):655-64.
1992: Justus Duyster; H Hidaka; K Decker; Peter Dieter
Proteinkinase C beta-isoform triggers the formation of prostanoids and superoxide in liver macrophages.
Biochemical and biophysical research communications 1992;183(3):1247-53.
1992: Justus Duyster; Agnes Schulze-Specking; E Fitzke; Peter Dieter
Protein kinase C involved in zymosan-induced release of arachidonic acid and superoxide but not in calcium ionophore-elicited arachidonic acid release or formation of prostaglandin E2 from added arachidonate.
Journal of cellular biochemistry 1992;48(3):288-95.
1991: Agnes Schulze-Specking; Justus Duyster; Peter J Gebicke-Haerter; S Wurster; Peter Dieter
Effect of fluoride, pertussis and cholera toxin on the release of arachidonic acid and the formation of prostaglandin E2, D2, superoxide and inositol phosphates in rat liver macrophages.
Cellular signalling 1991;3(6):599-606.